Skip to main content

 

The Biosafety Advisory Council (BAC) is one of the two pillars (with the Service Biosafety and Biotechnology - SBB) of the scientific evaluation system that has been set up in Belgium to advise the Federal and Regional competent authorities about the biosafety of activities involving genetically modified organisms (GMOs) and/or pathogens.
 
The Council is composed of 12 effective and 12 substitute members designated by the different Regional and Federal competent authorities. It is assisted in its scientific work by external experts from academic institutions and by the SBB. The secretariat of the Council is ensured by the SBB.


The Council advises the authorities for all regulatory dossiers related to the deliberate release of GMOs in the environment or the placing on the market of GMOs and GMO-based products. The Council can be consulted by the Regions for contained activities involving GMOs and/or pathogens (i.e. activities taking place in laboratories, greenhouses, animal husbandries, production plants or hospital rooms).

Latest news

Advice on application EFSA-GMO-RX-025 (genetically modified maize MIR162) from Syngenta intended for import and processing, food and feed
Advice on application EFSA-GMO-NL-2020-169 (genetically modified oilseed rape MON 94100) from Monsanto intended for import and processing, food and feed
Advice on application EFSA-GMO-NL-2018-151 (genetically modified maize MON89034 x1507 x MIR162 x NK603 x DAS-40278-9) from Dow AgroSciences intended for import and processing, food and feed
Advice on application EFSA-GMO-RX-020 (genetically modified soybean A5547-127) from BASF intended for import and processing, food and feed
Activity Report for 2021 of the Biosafety Advisory Council (in Dutch or in French)
Advice on dossier B/BE/21/BVW​​​​7: Phase 1 clinical trial (SCS Boehringer Ingelheim Ltd.) involving a GM Vesicular Stomatitis Virus (VSV) for treatment of advanced cancer (solid tumors)
Advice on application EFSA-GMO-NL-2018-150 (genetically modified maize DP4114 x MON810 x MIR604 x NK603) from Pioneer intended for import and processing, food and feed
Advice on dossier B/BE/21/BVW​​​​5: Phase 3 clinical trial (Sarepta Therapeutics) involving a GM Adeno Associated Virus (AAV) for treatment of Duchenne Muscular Dystrophy
Advice on dossier B/BE/21/BVW​​​​8: Phase 3 clinical trial (MeiraGTx UK II Limited) involving a recombinant, replication-incompetent, adeno-associated virus (AAV) viral vector for treatment of X-linked Retinitis Pigmentosa
Advice on dossier B/BE/22/V3​: Field trial (VIB) involving GM maize with modified growth characteristics